Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.
BACKGROUND Pim-3 kinase is a highly homologous serine/threonine kinase that is overexpressed in hematological malignancies and solid tumors. Few studies have been conducted to define the role of Pim-3 in solid tumors, especially in prostate cancer. The aim of this study was to define the role of Pim-3 in development and prognosis of prostate cancer. MATERIAL AND METHODS We collected specimens from 160 patients with prostate cancer, as well as 100 patients with benign prostatic hyperplasia. Realtime polymerase chain reaction was used for the assessment of Pim-3 expression at the RNA level and Western blot was used to quantify the Pim-3 protein synthesis in 3 different cell lines. RESULTS We found that Pim-3 mRNA expression in prostate cancer tissue was significantly higher than that in benign prostatic hyperplasia tissue (p<0.05). Accordingly, the protein level expression of Pim-3 in prostate cancer cell lines was also significantly higher than that in control cells. In addition, the expression status of Pim-3 mRNA was significantly associated with pathological parameters such as pre-surgery prostate specific antigen, Gleason score, pathological stage, and lymphoid metastasis. High expression of Pim-3 also significantly decreased the survival rate of patients after surgery. CONCLUSIONS Pim-3 expression is an important risk factor for prostate cancer; we are the first team to report Pim-3 as a valuable biomarker in Chinese.
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China (mainland).
Yanchun
Y
Qu
Department of Urology,, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China (mainland).
Changwen
C
Zhang
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China (mainland).
E
E
Du
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China (mainland).
Andi
A
Wang
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China (mainland).
Yuming
Y
Yang
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China (mainland).
Jianing
J
Guo
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China (mainland).
Aixiang
A
Wang
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China (mainland).
Zhihong
Z
Zhang
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China (mainland).
Yong
Y
Xu
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics / Q000378:metabolism; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D002681:China; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; C499249:PIM3 protein, human; D017346:Protein Serine-Threonine Kinases